Faculty

Joshua A. Beckman, MD, MSc

Professor of Medicine at Vanderbilt Medical School, Director of the Section of Vascular Medicine, and Director of the Cardiovascular Consultation Service at Vanderbilt University Medical Center

Dr. Joshua Beckman is a Professor of Medicine at Vanderbilt Medical School,
Director of the Section of Vascular Medicine, and Director of the Cardiovascular
Consultation Service at Vanderbilt University Medical Center. After earning his
MD from New York University School of Medicine, he completed medical
residency in internal medicine at Columbia Presbyterian Medical Center and
postgraduate fellowships in cardiovascular medicine and vascular medicine at
Brigham and Women's Hospital.

Dr. Beckman is the Director of the Section of Vascular Medicine within the Cardiovascular Division. Dr. Beckman is an award-winning educator and former cardiovascular disease fellowship director, having won the W. Procter Harvey Young Teacher Award from the American College of Cardiology, Jess R. Young Outstanding Vascular Medicine Educator Award from the Society of Vascular Medicine, and the Outpatient Teacher Award from the VUMC Cardiovascular Fellows. Dr. Beckman's research focuses on the mechanisms that cause vascular dysfunction, susceptibility to atherosclerosis, peripheral artery disease, and translating lab discoveries to human beings and is currently supported in this work by the NHLBI and as a Center Director for a Strategically Focused Research Network in Vascular Disease from the AHA. Dr. Beckman is the recent past Chair of the Peripheral Vascular Disease Council of the American Heart Association, past President for the Society for Vascular Medicine, and Chair-Elect of the ACC-AHA Joint Committee on Guidelines.

Deepak L. Bhatt MD, MPH, FACC, FAHA, FSCAI, FESC

Executive Director of Interventional Cardiovascular Programs at Brigham and Women’s Hospital and Professor of Medicine at Harvard Medical School

After graduating as valedictorian from Boston Latin School, Dr. Bhatt obtained his undergraduate science degree as a National Merit Scholar at MIT while also serving as a research associate at Harvard Medical School. He received his medical doctorate from Cornell University and a Master of Public Health with a concentration in clinical effectiveness from Harvard University.

His internship and residency in internal medicine were at the Hospital of the University of Pennsylvania, and his cardiovascular training was at Cleveland Clinic. He also completed fellowships in interventional cardiology and cerebral and peripheral vascular intervention and served as Chief Interventional Fellow at Cleveland Clinic, where he spent several years as an interventional cardiologist and an Associate Professor of Medicine. He served for many years as Director of the Interventional Cardiology Fellowship, Associate Director of the Cardiovascular Medicine Fellowship, and Associate Director of the Cardiovascular Coordinating Center. He was then recruited to be the Chief of Cardiology at VA Boston Healthcare System and served in that role for several years. He was a Senior Investigator in the TIMI Study Group for over a decade. He was selected by Brigham and Women’s Hospital as the 2014 Eugene Braunwald Scholar. He has been listed in Best Doctors in America from 2005 to 2020. He received the Eugene Braunwald Teaching Award for Excellence in the Teaching of Clinical Cardiology from Brigham and Women’s Hospital in 2017, ACC’s Distinguished Mentor Award in 2018, and AHA’s Distinguished Scientist Award in 2019. Dr. Bhatt has authored or co-authored over 1600 publications and has been listed by the Web of Science Group as a Highly Cited Researcher from 2014 to 2020. He is the Editor of Cardiovascular Intervention: A Companion to Braunwald’s Heart Disease and of Opie's Cardiovascular Drugs: A Companion to Braunwald's Heart Disease. He was the international PI for the CHARISMA and CRESCENDO trials and co-PI of the three CHAMPION trials. He served as chair of COGENT and co-PI of STAMPEDE. He serves as co-chair of the REACH registry and chairs REDUCE-IT, SOLOIST, and SCORED. He is co-PI of SAVOR-TIMI 53, SYMPLICITY HTN-3, THEMIS, and THEMIS-PCI. In 2014, he was listed in the AHA/ASA top advances in heart disease and stroke research (for STAMPEDE and SYMPLICITY HTN-3); in 2018, REDUCE-IT was listed and also named the top cardiology trial by NEJM; in 2020, SOLOIST and SCORED were listed by the AHA. He was the inaugural Chair of the AHA-GWTG Quality Oversight Committee. He served as a Trustee of the ACC. He is Senior Associate Editor for News and Clinical Trials for ACC.org. He is the Editor of the peer-reviewed Journal of Invasive Cardiology and Editor-in-Chief of the Harvard Heart Letter for patients.

Snehal H. Bhatt , MD

Professor of Pharmacy Practice at the MCPHS University, and Clinical Pharmacist

Snehal H. Bhatt is Professor of Pharmacy Practice at the MCPHS University, and Clinical Pharmacist at the Beth Israel Deaconess Medical Center, in Boston, MA. He teaches and practices in acute care cardiology, anticoagulation, clinical pharmacokinetics, and adult internal medicine. Dr. Bhatt is a Board Certified Pharmacotherapy Specialist (BCPS) with Added Qualifications in Cardiology. His scholarly interests include inpatient anticoagulation for the prevention and treatment of thrombosis, anticoagulation reversal therapies, and the role of the pharmacists in the management of cardiovascular disease.

Dr. Bhatt was awarded Fellow of the American Society of Health-System Pharmacists (ASHP) in 2017. As an active member of ASHP, Dr. Bhatt is currently a content matter expert and faculty member in ASHP’s BCPS recertification and preparatory course, a position he has held since 2015. He represented ASHP on the Joint Commission Technical Advisory Panel for National Patient Safety Goal 03.05.01-Reducing Harm from Anticoagulant Therapy: Update to Include Direct Oral Anticoagulants (DOACs). He also served on the ASHP Council on Therapeutics for 4 years, serving as Chair in 2019. Dr. Bhatt is also actively involved in the American College of Cardiology (ACC) where his leadership roles include serving on the Cardiovascular Team (CVT) Council, and the CV Team Education Committee. He has previously served as the CV Team Steering Committee Chair for the Northeast Region. Locally for the Massachusetts ACC. He was awarded Associate of the ACC (AACC) in 2018.

Marc P. Bonaca, MD, MPH, FAHA, FACC

Professor of Medicine at the University of Colorado Anschutz Medical Campus

Marc P. Bonaca, MD, MPH, FAHA, FACC is a cardiologist and vascular medicine specialist who serves as the executive director of CPC Clinical Research and Community Health, as well as Director of Vascular Research and Professor of Medicine at the University of Colorado Anschutz Medical Campus.

Dr. Bonaca earned his medical degree from the University of Connecticut School of Medicine and his MPH at Harvard University. He served as a cardiovascular research fellow with the TIMI Study Group with the Cardiovascular Division of Brigham and Women’s Hospital. After completion of his training, he joined the faculty at Brigham and Women’s Hospital and Harvard Medical School and became an investigator at the TIMI Study Group. He went on to serve as center director and clinical project principal investigator of the Brigham and Women’s Hospital and Dartmouth Hitchcock Center in the American Heart Association Strategically Focused Research Network in peripheral vascular disease. Dr. Bonaca’s research focus is on ischemic risk in patients with atherosclerotic vascular disease, risk prediction, and risk modification through the use of pharmacologic and biologic therapies. He has extensive experience in the design and conduct of large, multicenter randomized clinical trials, as well as analyses in registries and real-world datasets. His key areas of interest include patients with peripheral artery disease, polyvascular disease, and diabetes, with a focus on the breadth of risk including ischemic limb outcomes, microvascular complications, and major adverse cardiovascular events. In addition, he is actively investigating the cardiac, vascular, and thrombotic complications associated with novel oncologic therapies.

Christopher P. Cannon, MD

Boston, Massachusetts

Dr. Cannon is a Professor of Medicine at Harvard Medical School, and senior physician in the Cardiovascular Division at Brigham and Women’s Hospital. He currently serves as Education Director in the Cardiovascular Innovation group. He has worked for 25 years as an investigator in the TIMI Study Group, then for 5 years with the Harvard Clinical Research Institute (now Baim Institute).

Ricardo Correa, MD, EdD, FACE, FACP, FACMQ, FAPCR

Ricardo Correa is the Associate Professor, Program Director for Endocrinology, diabetes and metabolism fellowship and the Director for Diversity on GME for the University of Arizona College of Medicine-Phoenix. He serves as staff clinician and researcher at Phoenix VAMC. Additionally, he is faculty for The Mayo SOM-Arizona and for Creighton SOM-Phoenix Campus. He is an editor of Dynamed, Empower magazine, and outreach unit director of Endotext.org and Thyroid manager.

He completed his Medical School and master’s in education at The University of Panama. He completed a research fellowship in Epidemiology and Tropical disease at I.C.G.E.S. in Panama City and his internal medicine residency at Jackson Memorial Hospital-University of Miami program. Then, he pursued his clinical and research fellowship in endocrinology with a particular focus on neuroendocrinology and adrenals at the NIH. He is now pursuing formal training in diversity and inclusion and medical education with the AAMC. He has been involved in organized medicine since medical school. He has taken an active leadership role in multiple national organizations. Besides Endocrine, he has been involved with the local, regional and national organization in the area of medical education, leadership, and physician wellbeing. He practices clinical endocrinology, research and educational activities. He has been involved in multiple academic, scientific, and educational activities including article Consultant, Interpretation of the Medical Literature Project, NBME., International Committee, member of the Committee on publications Ethics (COPE), World Association of Medical Editors, Deputy Editor of International Archives of Medicine, Editorial board and peer reviewer of multiple journals and consultant for Latin-American science centers, including Bolivia and Panama national science department. At AACE Dr. Correa has occupied different positions from been the fellow-in-training board of director member to member and advisor of almost all the committees throughout the years. He was the chair of the young physician subcommittee and actual vice-chair of the CME committee, member of the clinical guidelines oversight committee, DEI committee and other committees and subcommittees. He is a Fellow of the American College of Endocrinologist (FACE). He is dedicated to the community and helps as the co-medical director for an underserved clinic in Phoenix, where he created the endo and diabetes clinic. He gives lectures and mentors many underrepresented minorities to become part of medicine. Due to all his career, Dr. Correa has been awarded several recognitions, including Presidential Leadership scholar, 100 Hispanic Inspiring Scientist, Medscape Rising Start, N.M.Q.F. 40 under 40, and many other prestigious national awards. “Our AACE has embraced diversity and inclusion as a full concept for the benefit of our patients, our members, our committees and our leadership. The practice of medicine and how physicians learn and interact have changed. Our AACE has done very well with the previous model of medicine but now has to adapt to the new changes. I am seeking election to the Board because I want to bring projects and programs that will foster this new vision and mission. I have the experienced to be involved in multiple organizations and understand how we can make changes for the benefit of everyone. I would like to bring that prior knowledge to AACE. Communications with members is a key issue. I will always try to connect to everyone and bring the different perspectives to the table when deliberating and making decision on behave of our AACE. I believe that “Together, we are AACE” expresses that we are a community, and it stimulates new members to join. Like any community, we have differences, but we fix our difference to achieve our goals when we come together as an organization.” I humbly ask your support for this nomination.

John Fanikos, R.Ph., MBA

Chief of Pharmacy Services Brigham and Women’s Hospital

John Fanikos, R.Ph., MBA, is Chief of Pharmacy Services at Brigham and Women's Hospital (BWH) in Boston, Massachusetts. He is responsible for the overall Pharmacy Department operations and its financial performance. Mr. Fanikos also serves as Adjunct Professor of Clinical Pharmacy at Massachusetts College of Pharmacy and Health Sciences (MCP). He earned his Bachelor of Science degree in Pharmacy at Massachusetts College of Pharmacy and his Master of Business Administration degree at Northeastern University. He completed an ASHP-accredited residency at BWH.

Mr. Fanikos has served in a number of different roles at BWH, including investigational drug pharmacist, inpatient and outpatient pharmacy supervisor, clinical preceptor, and pharmacy administrator. While fulfilling these roles, he has worked with patients on orthopedic, oncology, cardiology, and general medicine units. He now manages a staff of over 300 pharmacists, pharmacy technicians, and pharmacy interns that provide care across inpatient and ambulatory settings. As part of his research interests, he has worked closely with the BWH Thromboembolism Research Group for over 25 years. He has authored and co-authored over 100 peer reviewed articles and textbook chapters on medication use with a specific emphasis on optimizing medication utilization. His research focus has been identifying and avoiding the problems and pitfalls of medication use. Mr. Fanikos is a member of the National Comprehensive Cancer Network (NCCN) panel that crafts guidelines for the treatment and prevention of thromboembolic disease. He serves as the treasurer and sits on the Board of Directors for the North American Thrombosis Forum (NATF), a nonprofit organization that provides a platform for those interested in thrombotic disorders to enhance disease education, awareness, advocacy, research, and prevention. He also serves on the Board of Directors for the Hospital Quality Foundation (HQF). Like NATF, HQF is a 503C charitable organization, and it is dedicated to improving the quality of healthcare by supporting the development and delivery of education related to medical practice. Mr. Fanikos is Past President of the Massachusetts Society of Health-System Pharmacists. Both his father and brother are pharmacists, and graduates of MCP, which makes him aware of many of the issues challenging the medical professionals and college students today.

Dr Kevin Fernando, FRCGP FRCP Edin, FAcadMEd MSc Diabetes

GP Partner North Berwick Health Centre, UK Dr

Dr Fernando is a part-time GP Partner and GP Educational Supervisor at the North Berwick Health Centre, North Berwick, UK. He is also Scottish lead of the Primary Care Diabetes Society and an observer member of the Primary Care Cardiovascular Society. His other roles include RCGP Clinical Advisor for Diabetes & Multimorbidity and Education Director for GPnotebook Education.

Dr Fernando graduated from the University of Edinburgh, Edinburgh, UK in 2000 and holds both MRCGP and MRCP (UK) qualifications and has completed a master’s degree in diabetes, which he passed with distinction. Dr Fernando has been elected to the Fellowship of the Royal College of General Practitioners, the Royal College of Physicians of Edinburgh, and the Academy of Medical Educators for his work in diabetes and medical education.

C. Michael Gibson, M.S., M.D.

CEO of the combined non-profit Baim and PERFUSE research institutes at Harvard Medical School

C. Michael Gibson, M.S., M.D. is an interventional cardiologist, cardiovascular researcher & educator. He is the CEO of the combined non-profit Baim and PERFUSE research institutes at Harvard Medical School. The institutes have led over 1,000 studies, published 3,000 manuscripts in the peer review literature, and have led 60 FDA submissions from their network of 7,000 sites worldwide. In 2014, 2018 and 2019 Gibson was ranked as one of the world's most highly cited authors in all of science in the past decade by Thomson Reuters. His work has been cited over 107,000 times, and he has an H index of 118 and an i10- index of 469.

Dr. Gibson is a practicing interventional cardiologist who has held numerous leadership positions in medicine including positions as a Coronary Care Unit Director, a Cardiac Catheterization Laboratory Director, a Chief of Cardiology and as a Vice Chairman of Medicine at a hospital of over 1,000 physicians. Gibson has led phase 1-4 clinical trials, and cardiology megatrials of over 15,000 patients which eventuate in international approval of drugs like prasugrel, rivaroxaban, betrixaban and andexanet as well as devices such as one that alarms to alert a patient to heart attack. He is currently leading the randomized HEARTLINE trial of over 150,000 patients which is being conducted virtually at 1% of the cost of a traditional randomized trial. It is the largest randomized trial in cardiology history. For years, Gibson has been chosen as one of Boston's Top Doctors & U.S. News & World Report also lists Gibson as one of America's top doctors. As an innovator, Gibson invented measures of coronary blood flow that are widely used today (the TIMI frame count (cited 2,131 times), the TIMI myocardial perfusion grade (cited 1,089 times). Dr. Gibson obtained his BS, MS, and MD degrees at the University of Chicago where he was a Phi Beta Kappa and AOA graduate. He then went on to do his internship, residency and chief residency at the Brigham and Women's Hospital and his cardiology fellowship at the Beth Israel Deaconess Medical Center both at Harvard Medical School. Gibson founded WikiDoc.org and WikiPatient.org, widely viewed open source textbooks of medicine. He is Editor-In-Chief of >2,200 active contributors who have edited the content of over 100,000 chapters millions of times over the past 15 years. Gibson also founded www.clinicaltrialresults.org and has conducted >2,400 TV / video interviews. Gibson has over 440,000 followers on social media where he is a leading influencer, second only to Sanjay Gupta in some polls. Gibson is a member of the FDA’s cardiorenal panel.

Mikhail Kosiborod, MD, FACC, FAHA

Kansas City, MO

Dr. Mikhail Kosiborod is a cardiologist, the Vice President of Research at Saint Luke’s Health System, Executive Director of the Cardiometabolic Center Alliance, Director of Cardiometabolic Research and Co-Director of the Haverty Cardiometabolic Center of Excellence at Saint Luke’s Mid America Heart Institute, and Professor of Medicine at the University of Missouri-Kansas City. Dr. Kosiborod received training in clinical research, epidemiology and health policy through the Robert Wood Johnson Clinical Scholars Program, as well as clinical training in cardiovascular medicine at Yale University School of Medicine.

Dr. Kosiborod is an internationally recognized expert in the fields of diabetes and cardiovascular disease, cardiometabolic and cardiorenal syndromes, as well as quality of care and outcomes. Dr. Kosiborod has authored and co-authored over 250 peer-reviewed publications, including scientific statements and position documents. Dr. Kosiborod is involved in the leadership of multiple clinical trials and multi-center registries, and is currently the principal investigator of several investigator-initiated, multicenter trials in diabetes and cardiovascular disease.

Edgar V. Lerma, MD, FACP, FASN, FPSN (Hon)

Clinical Professor of Medicine with the Section of Nephrology at University of Illinois at Chicago

Edgar Lerma, MD, earned his Doctor of Medicine from the University of Santo Tomas Faculty of Medicine and Surgery in Manila, Philippines. He completed Residency Training in Internal Medicine at UIC/Mercy Hospital and Medical Center, where he also served as Chief Resident. He completed a Fellowship in Nephrology and Hypertension at Northwestern Memorial Hospital, the Feinberg School of Medicine at Northwestern University, and the Veterans Administration Lakeside Medical Center in Chicago, Illinois.

Dr. Lerma is a Diplomate in the Subspecialty of Nephrology with the American Board of Internal Medicine. He has authored more than 100 peer-reviewed publications and presentations; notable publications include Current Diagnosis & Treatment: Nephrology & Hypertension, Nephrology Secrets, and Henrich’s Principles and Practice of Dialysis. He has peer reviewed and served on editorial boards for numerous journals, and currently is Associate Editor for International Urology and Nephrology, Clinical Reviews in Bone and Mineral Metabolism, and Journal of Clinical Lipidology. At present, he holds the rank of Clinical Professor of Medicine with the Section of Nephrology at University of Illinois at Chicago. He serves as the Educational Coordinator for Nephrology with UIC/Advocate Christ Medical Center. In recognition of his clinical work and expertise, Dr. Lerma has been elected to Fellowship of the American College of Physicians, Fellowship of the American Society of Nephrology, Fellowship of the American Heart Association/ Council on Kidney in Cardiovascular Disease, Fellowship of the American Society of Hypertension, Fellowship of the National Lipid Association, Fellowship of the National Kidney Foundation, and Fellowship of the American Society of Diagnostic and Interventional Nephrology. He has also been recognized for teaching and has been the recipient of “Subspecialty Teaching Attending Physician of the Year” in 2006 and “Physician Recognition Award for Excellence in Academics” in 2011 from UIC/Advocate Christ Medical Center Internal Medicine Residency Training Program. Dr. Lerma’s research interests include CKD, hypertension, diabetic kidney disease, and bone and mineral disorders.

Jerrold H Levy, MD, FAHA, FCCM

Duke University Medical Center, Durham, NC, USA

Jerrold Levy is Professor of Anesthesiology, Critical Care, Surgery (Cardiothoracic) at Duke University Medical Center in Durham, NC. He obtained his medical degree from the University of Miami, where he was an intern in internal medicine, and undertook his residency in the Department of Anesthesiology of the Massachusetts General Hospital and Harvard Medical School in Boston, where he was also Chief Resident, and completed fellowships in both Respiratory ICU and Cardiac Anesthesiology. He previously was Professor, Deputy Chair for Research, and Chief of Cardiothoracic Anesthesiology at Emory University.

His clinical and research interests include anticoagulation and its reversal, therapeutic strategies to prevent and treat coagulopathy and acute inflammatory responses in critically ill patients, clinical applications of recombinant and purified protein concentrates, and pharmacologic approaches to treat shock. His clinical practice involves managing critically ill patients with cardiopulmonary dysfunction, shock, and extracorporeal circulation in the ICU. His current appointments include Chair of the Subcommittee on Perioperative and Critical Care Thrombosis and Hemostasis for the International Society of Thrombosis and Hemostasis, Executive Editor of Anesthesiology, and consultant to the FDA‘s Biologic Products Advisory Committee. He is an elected Fellow of the American Heart Association and Society of Critical Care Medicine and has authored over 500 publications, including original research articles, reviews, chapters, and editorials with over 70,000 citations and an h-index of 88. He is also fluent in French and conversational in Spanish and Japanese.

Evie Marcolini, MD, FAAEM, FACEP, FCCM

Associate Professor of Emergency Medicine and Neurology Geisel School of Medicine at Dartmouth

Dr. Marcolini earned her medical degree from University of Vermont College of Medicine, completed residency in Emergency Medicine at Maine Medical Center and fellowship in Surgical Critical Care at R Adams Cowley Shock Trauma Center. She is board certified in Emergency Medicine (ABMS) and Neurocritical Care (UCNS). She served as faculty at R Adams Cowley Shock Trauma Center and University of Maryland in Surgical Critical Care and Emergency Medicine, followed by faculty appointment in Emergency Medicine and Neurology at Yale, where she worked in Emergency Medicine, Surgical Critical Care and Neurocritical Care. She is now faculty at Geisel School of Medicine at Dartmouth in Emergency Medicine and Neurology and practices Emergency Medicine and Neurocritical Care.

She is a past Chair of the Critical Care Section and member of the ACEP Academic Affairs Committee. She is a national and international speaker and educator and passionate about the role of the Emergency Physician in improving outcome for patients with acute neurologic illness and injury. She is active as a clinical ethics consultant at Dartmouth and teaches at the Sherwin B. Nuland Summer Institute in Bioethics at Yale University. She has been awarded the SCCM Grenvik Family Award in Ethics. Dr. Marcolini speaks nationally and internationally on the topics of Neurology, Emergency Medicine and Neurocritical Care. She is the Co-Chair of the Vietnamese Society for Emergency Medicine annual conference. She also teaches in the field of Wilderness Medicine. She is an advisory board member of the American Foundation for Firearm Injury Reduction in Medicine (AFFIRM), and a member of Board of Directors for American Academy of Emergency Medicine.

Roxana Mehran, MD, FACC, FAHA, MSCAI, FESC

Dr. Mehran is Mount Sinai Professor in Cardiovascular Clinical Research and Outcomes as well as Professor of Medicine (cardiology) and Population Health Science and Policy at the Icahn School of Medicine at Mount Sinai, and is an internationally renowned interventional cardiologist and clinical research expert in the field of cardiovascular disease. A prolific researcher, she has served as principal investigator for numerous global studies, developed risk scores for bleeding and acute kidney injury, participates regularly in developing clinical guidelines, and has authored more than 900 peer-reviewed articles. She has been included in Clarivate Analytics: The most influential scientific minds as one of the highly cited researchers for several consecutive years.

As a clinical trials expert in the field of interventional cardiology, Dr. Mehran specializes in multicenter, multinational clinical trials with complex data analyses and outcomes research. Her extensive research interests include mechanisms of neointima formation and restenosis, treatment and prevention of acute kidney injury in cardiac patients, gender and women’s-centered studies, and advancing pharmacologic and interventional treatments for acute coronary syndromes and acute myocardial infarction. Dr. Mehran possesses over 20 years of experience working with regulatory agencies to design and conduct clinical trials and help shape health policy and clinical standards and guidelines. She has served as the principal investigator (PI) or Co-PI for more than a dozen national and international multicenter randomized trials and is currently one of several lead investigators to collaborate with the FDA to develop standard definitions for clinical trials in cardiovascular disease. Dr. Mehran has presented over 1,200 abstracts at national and international conferences including TCT, AHA, ACC, ESC, EuroPCR, and SCAI. She is frequently featured as a keynote speaker.

Charles Victor Pollack, Jr., M.A., M.D., FACEP, FAAEM, FAHA, FACC, FESC, FCPP

Clinician-Scientist in the Department of Emergency Medicine at the University of Mississippi School of Medicine

Dr. Charles Pollack is a Clinician-Scientist in the Department of Emergency Medicine at the University of Mississippi School of Medicine. He has long been active in teaching and clinical research and is an international leader in emergency medicine. He is the only physician to have received the American College of Emergency Physicians’ highest national awards in both teaching and research; he also received the national teaching award from the Council of Emergency Medicine Residency Directors. He is the only US emergency physician to be elected a Fellow of the European Society of Cardiology. His primary research interests are in the management of thrombosis, reversal of anticoagulation, and other aspects of critical care. From 2015-2019, Dr. Pollack served in multiple additional roles at Thomas Jefferson University in Philadelphia: Associate Provost for Innovation in Education; Director, Jefferson Institute of Emerging Health Professions; Associate Dean for CME and Strategic Partner Alliances; and, Professor and Senior Advisor for Interdisciplinary Research and Clinical Trials, Department of Emergency Medicine. From 2001-2015, Dr. Pollack was Professor of Emergency Medicine at the Perelman School of Medicine of the University of Pennsylvania and served as Chairman of Emergency Medicine at Pennsylvania Hospital in Philadelphia. From 1992-2001, Dr. Pollack served in various positions in the Department of Emergency Medicine at Maricopa Medical Center in Phoenix, Arizona, an urban, tertiary care teaching hospital affiliated with the Medical College of the University of Arizona and the Mayo Graduate School of Medicine. He was Research Director from 1994 to 2000, and he chaired the department from 1997 to 2001. From 2000 through mid-2001, Dr. Pollack was also Director of Emergency Medicine at Arizona Heart Hospital. Dr. Pollack graduated summa cum laude from Emory University in 1980 with bachelor’s degrees in history and chemistry and with a master’s degree in the history of science and medicine. He was elected to Phi Beta Kappa. Dr. Pollack earned his medical degree from Tulane University School of Medicine and is a member of Alpha Omega Alpha. Dr. Pollack has written more than 500 original research articles, chapters, and abstracts, and serves on the editorial boards of several journals and on the steering committees of multiple national and international studies. He is the principal investigator on multiple ongoing trials and studies. He is also a strong advocate for entrepreneurism and innovation in healthcare. He is a founding Board member of the Hospital Quality Foundation, a non-for-profit education and research organization dedicated to improvement in the quality of care provided to patients in the hospital and at transition back to the outpatient setting.

Richard E. Pratley, MD

Samuel E. Crockett Chair in Diabetes Research, Senior Investigator and Diabetes Program Lead at the AdventHealth Translational Research Institute

Dr. Richard Pratley serves as Samuel E. Crockett Chair in Diabetes Research, Senior Investigator and Diabetes Program Lead at the AdventHealth Translational Research Institute, and Medical Director at the AdventHealth Diabetes Institute, in Orlando, Florida. He is also an Adjunct Professor of Medicine with the Johns Hopkins University School of Medicine. Dr. Pratley is an internationally recognized expert in diabetes and is board certified in internal medicine.

He received his MD from Wayne State University in Detroit and completed fellowships in geriatric medicine and gerontology at the University of Michigan, Johns Hopkins University, and the National Institute on Aging. As a member of the American Diabetes Association, the European Association for the Study of Diabetes and The Obesity Society, Dr. Pratley continues his active involvement in the professional community. He is on the editorial board for Diabetes, Obesity and Metabolism, has served as a member of the editorial boards of Diabetes Care, The Lancet: Diabetes and Endocrinology, The Journal of Diabetes and its Complications and The Journal of Clinical Endocrinology and Metabolism, and acts as an ad hoc reviewer for many other journals. Dr. Pratley regularly presents at national and international meetings, has conducted numerous research studies on the pathogenesis, prevention and treatment of diabetes, and has published over 280 peer-reviewed articles on diabetes and its complications. His current research interests include the prevention of diabetes, improving care for older persons with diabetes, developing new drugs to treat and prevent diabetes and its complications, and understanding the role of the fat cell in increasing the risk of diabetes and heart disease.

Sunil V. Rao, MD, FACC, FSCAI

Professor of Medicine at Duke University Medical Center, and the Section Chief of Cardiology at the Durham VA Medical Center

Dr. Rao is Professor of Medicine at Duke University Medical Center, and the Section Chief of Cardiology at the Durham VA Medical Center. At the national level, Dr. Rao serves as the Editor-in-Chief for Circulation Cardiovascular Interventions, the interventional journal of the American Heart Association’s flagship Circulation family of journals.

He is the Vice President of The Society for Cardiovascular Angiography and Interventions, and serves on the program committees of the ACC Scientific Sessions, the Transcatheter Cardiovascular Therapeutics conference, and the SCAI Scientific Sessions. He was the chairman of the 2017 ACC-i2 Summit and was the chair of the SCAI 2019 Annual Scientific Session. In addition, he was the Editor-in-Chief of the ACC CathSAP 5 program and is currently the co-chair of the ACC Collaborative Management Pathway for Interventional Cardiology. His main research interests are pharmacological and interventional therapies for acute coronary syndromes, as well as bleeding and blood transfusion complications among patients with ischemic heart disease. Dr. Rao has published over 300 peer-reviewed papers, and is the co-Editor-in-Chief of the seminal textbook on transradial procedures titled “Best Practices for Transradial Approach in Diagnostic Angiography and Intervention.”

Muthiah Vaduganathan, MD MPH FACC

Cardiologist at Brigham and Women’s Hospital and Harvard Medical School (Boston, MA)

Muthiah Vaduganathan, MD MPH FACC is a cardiologist at Brigham and Women’s Hospital and Harvard Medical School (Boston, MA). His research focuses on drug development, clinical trials, and implementation of cardio-renal-metabolic therapies. He has authored or co-authored more than 400 peer-reviewed publications. Dr. Vaduganathan serves on the editorial boards of the European Journal of Heart Failure, JACC Heart Failure (Social Media / CME Editor), & JACC (FIT / Early Career Section Editor). He participates as an investigator and Clinical Endpoints Committee member for ongoing advanced-phase trials in HF and cardiometabolic medicine.

Cardiometabolic Medicine

@cardiomet_CE on Twitter

Accredited by:

AcademicCME is jointly accredited by ACCME, ACPE & ANCC, to provide complimentary continuing education for the healthcare team.

Learn More at AcademicCME.com